← Back to Clinical Trials
Recruiting NCT06040073

NCT06040073 Natural History of Coronary Atherosclerosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06040073
Status Recruiting
Phase
Sponsor China National Center for Cardiovascular Diseases
Condition Coronary Artery Disease Progression
Study Type OBSERVATIONAL
Enrollment 125 participants
Start Date 2024-07-07
Primary Completion 2025-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 125 participants in total. It began in 2024-07-07 with a primary completion date of 2025-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The present study sought to explore the predictive value of radial wall strain (RWS, derived solely from angiograms) for coronary artery lesion progression compared with lesion vulnerability assessed by optical coherence tomography (OCT). The lesion progression at 1 year was defined as an increase of ≥20% in diameter stenosis based on quantitative coronary angiography (QCA) evaluation.

Eligibility Criteria

Inclusion Criteria: * General Inclusion Criteria: 1. Age ≥18 years 2. Acute myocardial infarction ≤ 45 days 3. Planned coronary angiography examination or potential interventional treatment * Angiographic Inclusion Criteria: 1. The presence of at least 1 non-flow-restricting lesion (visually estimated diameter stenosis: 30%-80%; QFR \> 0.80) in any non-infarct related artery with RVD ≥2.5 mm by visual assessment Exclusion Criteria: * General exclusion Criteria: 1. Cardiogenic shock 2. Pregnant or woman of child-bearing potential 3. Life expectancy less than 1 year for non-cardiac causes 4. Unable to tolerate contrast agents or anticoagulant/antiplatelet therapy 5. Prior CABG or planned CABG * Angiographic exclusion Criteria: 1. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification, branch ostium cannot be shown clearly, severe overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to QFR or RWS measurement 2. An interrogated lesion require surgical bypass grafting 3. Unable to judge culprit lesion or infarct-related artery according to current evidence

Contact & Investigator

Central Contact

Lei Song, MD

✉ drsong@vip.163.com

📞 01088322564

Principal Investigator

Lei Song, MD

PRINCIPAL INVESTIGATOR

Chinese Academy of Medical Sciences, Fuwai Hospital

Frequently Asked Questions

Who can join the NCT06040073 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease Progression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06040073 currently recruiting?

Yes, NCT06040073 is actively recruiting participants. Contact the research team at drsong@vip.163.com for enrollment information.

Where is the NCT06040073 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06040073 clinical trial?

NCT06040073 is sponsored by China National Center for Cardiovascular Diseases. The principal investigator is Lei Song, MD at Chinese Academy of Medical Sciences, Fuwai Hospital. The trial plans to enroll 125 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology